Page 44 - T Cell News Today

Researchers describe the impact of changes in the Omicron variant on a uniquely immunodominant spike-encoded CD8+ T-cell epitope.

Researchers discuss the progression of SARS-CoV-2 infection throughout the respiratory epithelium.

Researchers assess the correlation between humoral and cell-mediated responses to SARS-CoV-2 in symptomatic and asymptomatic individuals.

Researchers identify 17 individuals who were infected with a highly virulent variant of HIV-1.

In a recent study published in the latest issue of the journal Cell, a team of researchers evaluated T-cell reactivity to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant's spike (S) and non-spike proteins.

A new study analyzes neutralizing antibodies and T-cell responses targeting the SARS-CoV-2 D614G, as well as some variants of concern.

In a new study, a team of researchers assessed the affinity of the SARS-CoV-2 Omicron variant of concern towards major histocompatibility complex (MHC) binding

In a new study, a team of researchers developed a hybrid vaccine for SARS-CoV-2 and influenza viruses using influenza virus-like particles (VLP).

Two patients with chronic lymphocytic leukemia who were among the first to receive the groundbreaking therapy were still in remission a decade later.

Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted antigens on cancer cells – a "back up" approach that promises to greatly reduce the potential for antigen escape currently found in CAR T therapies that solely target CD19.